How to Use an SBA Loan to Buy a Lab & Diagnostics Company

Before approaching a lender, confirm the lab is a viable SBA candidate. Obtain three years of accrual-based financial statements and tax returns, calculate normalized EBITDA after adding back owner compensation and one-time expenses, and verify the business's CLIA certification, CAP accreditation status, state laboratory licensure, and payer contract portfolio. Flag any open CMS audits, OIG issues, or billing compliance concerns immediately — these must be resolved or disclosed early to avoid surprises in underwriting. Review the equipment inventory to estimate remaining useful life and near-term capex exposure, which will affect the lender's collateral valuation and your overall financing structure.

Not all SBA lenders understand the regulatory and operational complexity of clinical laboratory acquisitions. Seek out Preferred Lender Program (PLP) banks or non-bank SBA lenders who have closed healthcare services transactions and are familiar with CLIA certification continuity, payer contract assignment requirements, and healthcare revenue cycle underwriting. Ask specifically whether the lender has financed laboratory or diagnostics acquisitions before and request references. A lender unfamiliar with healthcare will apply generic underwriting assumptions that may undervalue the business or create unnecessary conditions. Working with a healthcare-focused SBA lender typically accelerates approval by 4–6 weeks.

Structure your LOI to reflect the realities of lab deal dynamics. Include provisions for an exclusivity period of at least 60–90 days to allow time for SBA underwriting and regulatory diligence. Address payer contract assignment upfront — specify that the seller will cooperate with payer notification requirements during the SBA approval period. Agree on an asset purchase versus stock purchase structure early, as this affects how CLIA certification and payer contracts transfer and has direct implications for SBA collateral and indemnification arrangements. Include a seller financing component of 10–15% on full standby if needed to reach your equity injection target. Avoid earnout structures that complicate SBA loan eligibility without first confirming lender acceptance.

Prepare a comprehensive loan package including: completed SBA Form 1919 (borrower information) and Form 912 (statement of personal history); three years of business tax returns and financial statements; current accounts receivable aging and payer mix breakdown; personal financial statements and three years of personal tax returns for all 20%+ owners; a business plan demonstrating post-acquisition operational continuity; documentation of CLIA certification, CAP accreditation, and state licensure; copies of key payer contracts with reimbursement rates and renewal dates; equipment appraisals or vendor assessments for major diagnostic instrumentation; and a description of the buyer's operational and clinical qualifications. Labs with Medicare/Medicaid billing will require the lender to conduct heightened compliance review — be prepared to provide billing system reports, denial rates, and DSO metrics.

Conduct simultaneous regulatory, financial, and operational due diligence while the lender underwrites. Engage a healthcare regulatory attorney to review CLIA change-of-ownership procedures, state licensure transfer requirements, and payer contract assignment clauses — particularly Medicare provider agreement continuity under the 72-hour rule or tie-in notices. Commission an independent equipment appraisal to support collateral valuation. Obtain a billing compliance review from a qualified healthcare compliance firm to identify any coding inaccuracies, audit exposure, or overpayment risks that must be resolved before or at close. Assess lab director and technical staff retention risk and document any employment or retention agreements in place. Surface any issues during this phase rather than post-close — lenders will typically require resolution of material compliance findings before funding.

Address all SBA lender conditions promptly. Common conditions in lab acquisitions include: proof of CLIA certification transfer or continuation approval, evidence that key payer contracts have been notified and assigned or that assignment is in process, employment agreements for the lab director and any medical director, verification that no OIG exclusions apply to the seller or key staff, and confirmation of adequate liability and malpractice insurance for the acquiring entity. Work with your attorney to structure the closing to sequence regulatory transfers correctly — in most states, the new CLIA certificate must be applied for and the Medicare provider agreement must be addressed before or immediately at close to avoid billing disruption. Coordinate with the seller to ensure a clean handoff of specimen routing, requisition forms, and client communications.

At closing, ensure all SBA loan proceeds are disbursed correctly, seller note documentation is executed, and escrow holdbacks (if any) are funded per the purchase agreement. Immediately implement your transition plan: notify referring physician groups of the ownership change, introduce yourself to key accounts, retain and reassure clinical staff, and confirm that all billing systems are updated to reflect the new entity's NPI, tax ID, and payer contract numbers. Monitor denial rates and DSO closely in the first 90 days — billing disruptions during ownership transitions are common in labs and can erode cash flow faster than expected. Maintain close communication with your SBA lender throughout the transition period, particularly if any payer contracts require extended reassignment timelines.